Literature DB >> 25410665

Growth patterns in children with mucopolysaccharidosis I and II.

Agnieszka Różdżyńska-Świątkowska1, Agnieszka Jurecka, Joachim Cieślik, Anna Tylki-Szymańska.   

Abstract

BACKGROUND: Mucopolysaccharidosis (MPS) diseases lead to a profound disruption in normal mechanisms of growth and development. This study was undertaken to determine the general growth of children with MPS I and II.
METHODS: The anthropometric data of patients with MPS I and II (n=76) were retrospectively analyzed. The growth patterns of these patients were analyzed and then plotted onto Polish reference charts. Longitudinal analyses were performed to estimate age-related changes.
RESULTS: At the time of birth, the body length was greater than reference charts for all MPS groups (Hurler syndrome, P=0.006; attenuated MPS II, P=0.011; severe MPS II, P<0.001). The mean z-score values for every MPS group showed that until the 30th month of life, the growth patterns for all patients were similar. Afterwards, these growth patterns start to differ for individual groups. The body height below the 3rd percentile was achieved around the 30th month for boys with Hurler syndrome, between the 4th and 5th year for patients with severe MPS II and between the 7th and 8th year for patients with attenuated MPS II.
CONCLUSIONS: The growth pattern differs between patients with MPS I and II. It reflects the clinical severity of MPS and may assist in the evaluation of clinical efficacy of available therapies.

Entities:  

Mesh:

Year:  2014        PMID: 25410665     DOI: 10.1007/s12519-014-0517-6

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  21 in total

Review 1.  The clinical spectrum of alpha-L-iduronidase deficiency.

Authors:  M Roubicek; J Gehler; J Spranger
Journal:  Am J Med Genet       Date:  1985-03

2.  Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses.

Authors:  C M Simonaro; M E Haskins; E H Schuchman
Journal:  Lab Invest       Date:  2001-09       Impact factor: 5.662

3.  Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II.

Authors:  Agnieszka Rozdzynska; Anna Tylki-Szymanska; Agnieszka Jurecka; Joachim Cieslik
Journal:  Acta Paediatr       Date:  2010-11-05       Impact factor: 2.299

4.  Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

Authors:  Stuart J Swiedler; Michael Beck; Manal Bajbouj; Roberto Giugliani; Ida Schwartz; Paul Harmatz; James E Wraith; Jane Roberts; David Ketteridge; John J Hopwood; Nathalie Guffon; M Clara Sá Miranda; Elisa Leão Teles; Kenneth I Berger; Cheri Piscia-Nichols
Journal:  Am J Med Genet A       Date:  2005-04-15       Impact factor: 2.802

5.  Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype.

Authors:  Marlies J Valstar; Hennie T Bruggenwirth; Renske Olmer; Ron A Wevers; Frans W Verheijen; Ben J Poorthuis; Dicky J Halley; Frits A Wijburg
Journal:  J Inherit Metab Dis       Date:  2010-09-18       Impact factor: 4.982

6.  Growth charts for patients affected with Morquio A disease.

Authors:  Adriana M Montaño; Shunji Tomatsu; Ana Brusius; Mary Smith; Tadao Orii
Journal:  Am J Med Genet A       Date:  2008-05-15       Impact factor: 2.802

7.  Mild form of Hunter's syndrome: clinical delineation based on 31 cases.

Authors:  I D Young; P S Harper
Journal:  Arch Dis Child       Date:  1982-11       Impact factor: 3.791

8.  Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.

Authors:  Lorne A Clarke; J Edmond Wraith; Michael Beck; Edwin H Kolodny; Gregory M Pastores; Joseph Muenzer; David M Rapoport; Kenneth I Berger; Marisa Sidman; Emil D Kakkis; Gerald F Cox
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

Review 9.  Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.

Authors:  J Edmond Wraith; Maurizio Scarpa; Michael Beck; Olaf A Bodamer; Linda De Meirleir; Nathalie Guffon; Allan Meldgaard Lund; Gunilla Malm; Ans T Van der Ploeg; Jiri Zeman
Journal:  Eur J Pediatr       Date:  2007-11-23       Impact factor: 3.183

10.  The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.

Authors:  Zbigniew Żuber; Agnieszka Różdżyńska-Świątkowska; Agnieszka Jurecka; Anna Tylki-Szymańska
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

View more
  15 in total

Review 1.  Growth impairment in mucopolysaccharidoses.

Authors:  Melodie Melbouci; Robert W Mason; Yasuyuki Suzuki; Toshiyuki Fukao; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-03-16       Impact factor: 4.797

Review 2.  Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future.

Authors:  Hui Hsuan Chen; Kazuki Sawamoto; Robert W Mason; Hironori Kobayashi; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii; Shunji Tomatsu
Journal:  J Hum Genet       Date:  2019-08-27       Impact factor: 3.172

3.  Predictors of growth patterns in children with mucopolysaccharidosis I after haematopoietic stem cell transplantation.

Authors:  Stefanie Maier; Miroslav Zivicnjak; Lorenz Grigull; Julia B Hennermann; Charlotte Aries; Britta Maecker-Kolhoff; Martin Sauer; Anibh M Das; Rita Beier
Journal:  JIMD Rep       Date:  2022-04-26

Review 4.  Failures of Endochondral Ossification in the Mucopolysaccharidoses.

Authors:  Zhirui Jiang; Sharon Byers; Margret L Casal; Lachlan J Smith
Journal:  Curr Osteoporos Rep       Date:  2020-10-16       Impact factor: 5.096

5.  Short stature as a presenting symptom of attenuated Mucopolysaccharidosis type I: case report and clinical insights.

Authors:  Ana Maria Martins; Kristin Lindstrom; Sandra Obikawa Kyosen; Maria Veronica Munoz-Rojas; Nathan Thibault; Lynda E Polgreen
Journal:  BMC Endocr Disord       Date:  2018-11-12       Impact factor: 2.763

6.  Easy-to-use algorithm would provide faster diagnoses for mucopolysaccharidosis type I and enable patients to receive earlier treatment.

Authors:  Anna Tylki-Szymańska; Linda De Meirleir; Maja Di Rocco; Waseem M Fathalla; Nathalie Guffon; Christina Lampe; Allan M Lund; Rossella Parini; Frits A Wijburg; Jiri Zeman; Maurizio Scarpa
Journal:  Acta Paediatr       Date:  2018-08       Impact factor: 2.299

7.  Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III).

Authors:  Nicole M Muschol; Daniel Pape; Kai Kossow; Kurt Ullrich; Laila Arash-Kaps; Julia B Hennermann; Ralf Stücker; Sandra R Breyer
Journal:  Orphanet J Rare Dis       Date:  2019-05-02       Impact factor: 4.123

8.  Growth impairment and limited range of joint motion in children should raise suspicion of an attenuated form of mucopolysaccharidosis: expert opinion.

Authors:  Nathalie Guffon; Pierre Journeau; Anaïs Brassier; Juliane Leger; Bertrand Chevallier
Journal:  Eur J Pediatr       Date:  2019-02-11       Impact factor: 3.183

Review 9.  Dental-craniofacial manifestation and treatment of rare diseases.

Authors:  En Luo; Hanghang Liu; Qiucheng Zhao; Bing Shi; Qianming Chen
Journal:  Int J Oral Sci       Date:  2019-02-20       Impact factor: 6.344

10.  Birth weight in patients with mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS).

Authors:  Olaf Bodamer; Maurizio Scarpa; Christina Hung; Tom Pulles; Roberto Giugliani
Journal:  Mol Genet Metab Rep       Date:  2017-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.